Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by Rhumbline Advisers

Rhumbline Advisers increased its holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 488.3% in the second quarter, HoldingsChannel.com reports. The firm owned 103,258 shares of the company’s stock after buying an additional 85,706 shares during the quarter. Rhumbline Advisers’ holdings in Neumora Therapeutics were worth $1,015,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Principal Financial Group Inc. acquired a new stake in shares of Neumora Therapeutics in the second quarter worth approximately $166,000. SG Americas Securities LLC purchased a new stake in shares of Neumora Therapeutics in the second quarter valued at about $566,000. Nan Fung Group Holdings Ltd purchased a new stake in shares of Neumora Therapeutics during the 1st quarter valued at approximately $871,000. Auour Investments LLC purchased a new stake in shares of Neumora Therapeutics during the 1st quarter valued at approximately $1,445,000. Finally, Kennedy Capital Management LLC purchased a new stake in shares of Neumora Therapeutics during the 1st quarter valued at approximately $1,881,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Neumora Therapeutics

In related news, CFO Joshua Pinto sold 31,642 shares of Neumora Therapeutics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $11.78, for a total value of $372,742.76. Following the completion of the transaction, the chief financial officer now directly owns 154,658 shares in the company, valued at $1,821,871.24. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Neumora Therapeutics news, CFO Joshua Pinto sold 31,642 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $11.78, for a total transaction of $372,742.76. Following the completion of the transaction, the chief financial officer now owns 154,658 shares in the company, valued at approximately $1,821,871.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Robert A. Lenz sold 30,788 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total transaction of $363,606.28. Following the completion of the sale, the insider now owns 339,205 shares in the company, valued at $4,006,011.05. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 90,926 shares of company stock valued at $1,067,758. 26.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on NMRA shares. Royal Bank of Canada reissued an “outperform” rating and set a $29.00 target price on shares of Neumora Therapeutics in a research note on Wednesday, September 4th. Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a report on Thursday, September 12th. Finally, Mizuho began coverage on shares of Neumora Therapeutics in a research report on Monday, July 8th. They issued an “outperform” rating and a $20.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $22.11.

Neumora Therapeutics Stock Up 1.5 %

NASDAQ NMRA opened at $12.92 on Monday. The stock has a 50-day moving average of $11.74 and a two-hundred day moving average of $11.36. Neumora Therapeutics, Inc. has a 1-year low of $8.33 and a 1-year high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). On average, sell-side analysts forecast that Neumora Therapeutics, Inc. will post -1.51 EPS for the current year.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.